Robert P. Charrow: Lawyer with Greenberg Traurig, LLP

Robert P. Charrow

LinkedIn
Shareholder
Washington,  DC  U.S.A.
Phone202.533.2396

Peer Rating
 5.0/5.0
AV® Preeminent

Client Rating

Featured AV Peer Review Rated Lawyer IconFeatured AV Peer Review Rated Lawyer Icon
Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials Ratings & Reviews
 

Practice Areas

  • Health & FDA Business
  • Pharmaceutical, Medical Device & Health Care Litigation
  • Life Sciences & Medical Technology
 
Contact InfoTelephone: 202.533.2396
Fax: 202.331.3101
http://www.gtlaw.com/People/Robert-P-Charrow
 
University Harvey Mudd College, B.S., 1966
 
Law SchoolStanford Law School, J.D., 1969
 
Admitted1970, California; 1979, District of Columbia; Supreme Court of the United States; U.S. Court of Appeals for the District of Columbia Circuit; U.S. Court of Appeals for the Federal Circuit; U.S. Court of Appeals for the Fifth Circuit; U.S. Court of Appeals for the Fourth Circuit; U.S. Court of Appeals for the Ninth Circuit; U.S. Court of Appeals for the Second Circuit; U.S. Court of Appeals for the Seventh Circuit; U.S. Court of Appeals for the Third Circuit
 
Memberships American Bar Association (Vice Chair, Clinical Research Interest Group, Health Law Section).
 
BornSt. Louis, Missouri, October 21, 1944
 
Biography

Robert Charrow focuses his practice on research, biotechnology and health care issues. He represents health care providers, scientists, pharmaceutical companies, universities, research institutes and other entities with respect to legislative, regulatory and litigation matters arising under the Federal Food, Drug, and Cosmetic Act; research issues under the Public Health Service Act; licensing issues under the Federal Technology Transfer Act, the Bayh-Dole Act and related legislation; and reimbursement and regulatory issues under Medicare and Medicaid, the False Claims Act and other federal laws.

Robert represents corporations, political action committees and candidate committees with respect to issues arising under the Federal Election Campaign Act of 1971, as amended, and ancillary legislation. He also participates regularly in preparing Supreme Court briefs and certiorari petitions. Prior to joining the firm, Robert served as Deputy General Counsel and Principal Deputy General Counsel for the U.S. Department of Health and Human Services. Robert also supervised the Chief Counsel for the various agencies within the department, including the Food and Drug Administration, the Health Care Financing Administration, and the Office of Inspector General and the Public Health Service. He actively participated in formulating department policy with respect to Medicare reimbursement, drug and device approvals, tort liability, and technology transfer.

Robert served as a member of the senior staff at the AIDS Coordinating Council, the Attorney General's Task Force on Tort Reform, and the Secretary's Task Force on Medical Liability, and was Chairman of the Task Force on Scientific Misconduct. He served as Deputy Chief Counsel to Reagan-Bush '84, the President's authorized campaign committee, and also taught as an Associate Professor of Law at University of Cincinnati College of Law.

Robert has written extensively in the area of science and the law, and in particular on the effects of the legal system on scientific research, product development and health.

Areas of Concentration

· Health law

· Appellate litigation

· Administrative law

· Food, drug and cosmetic law

· Tort law

· Litigation

· Campaign finance law

Professional & Community Involvement

· Co-Principal Investigator, National Science Foundation

· Member, Advisory Board, BNA Medical Research Law & Policy Report

· Member, American Law Institute

· Member, Board of Advisors, Institute of Human Virology, University of Maryland

· Member, Secretary's Advisory Committee on Organ Transplantation

· Vice Chair, American Bar Association, Health Law Section, Clinical Research Interest Group

Awards & Recognition

· Team Member, a Law360 "Appellate Practice Group of the Year," 2010

· Rated, AV Preeminent® 5.0 out of 5

Professional Experience

Significant Representations

· Murphy Bros., Inc. v. Michetti Pipe Stringing, 526 U.S. 344 (1999)

· Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999)

· United States v. Winstar Corp., 518 U.S. 839 (1996)

· Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996)

· Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)

· Sherley v. Sebelius, 644 F.3d 388 (D.C. Cir. 2011)

· Cacchillo v. Insmed, Inc., 638 F.3d 401 (2nd Cir. 2011)

· Mann v. Heckler & Koch Def., 630 F.3d 338 (4th Cir. 2010)

· Schering-Plough Healthcare Prods., Inc. v. Schwarz Pharma, Inc., 586 F.3d 500 (7th Cir. 2009)

· Chamber of Commerce of the United States of Am. v. Chertoff, 552 F.Supp.2d 999 (N.D. Cal. 2007), appeal dismissed, No. 07-17241 (9th Cir. Nov. 7, 2009)

· Shotz v. American Airlines, Inc., 420 F.3d 1332 (11th Cir. 2005)

· In Re Estate of Sigourney, 93 Cal.App.4th 593 (2001)

· NAPHS v. Shalala, 120 F. Supp.2d 33 (D.D.C. 2000)

Publications & Presentations

Articles, Lectures & Publications

Articles

· Co-Author, "Lessons From Intermountain's Stark Law Settlement," Law360, April 11, 2013

· Author, "Protection of Human Subjects: Is Expensive Regulation Counter-Productive?" 101Nw.U.L. REV. 707, 2007

· Co-Author, "Institutional Review Boards - Are They Science's Answer to Hollywood's Hays Board?" BNA's Medical Research Law & Policy Report, July 5, 2006

· Co-Author, "Regulation of Clinical Trials by the FDA: A Process in Search of Procedures,"BNA's Medical Research Law & Policy Report, February 4, 2004

· Author, "The Federal Research Grant-Renaissance Patronage with Legal Formalities,"BNA's Medical Research Law & Policy Report, May 1, 2002

· Author, "The HIPAA Quagmire: Can Electronic Privacy Be Enhanced Constitutionally by a Paperwork Rule?" Health Care Review, June 2001

· Co-Author, "Biomedical Research-Human Subjects Protection," National Law Journal, October 30, 2000

· Author, "Advisory Committees and the Federal Regulation of Biomedical Research," Journal of Biolaw & Business, May, 1999

· Co-Author, "ERISA Pre-Emption---A Law in Search of a Doctrine," Health Law Digest, March 1999

· Author, "Changes At An Old Club: A Primer on Rules of the House," Journal of National Institutes of Health Research, January 1995

· Author, "The Legacy of Queen Anne: A Primer on Copyright Law," Journal of National Institutes of Health Research, February 1995

· Co-Author, "Following the Supreme Court's Analysis in Cipollone, Courts are Finding Broad Preemption in Sophisticated Medical Device Tort Litigation," Journal of Products & Toxics Liability, 1995

· Author, "Scientific Misconduct Five Years Later," Journal of National Institutes of Health Research, May 1994

· Author, "Whose Tissue Is It Anyway?" Journal of National Institutes of Health Research, December 1994

· Author, "An AIDS Vaccine: It May Take an Act of Congress," Journal of National Institutes of Health, June 1994

Books

· Author, Law in the Laboratory: A Guide to the Ethics of Federally Funded Science Research, University of Chicago Press, Chicago, IL, 2010

· Co-Author, Clear & Effective Legal Writing, Aspen Publishers, 4th ed., New York, NY, 2007

· Co-Author, Scientific Evidence in the Courtroom: Admissibility and Statistical Significance After Daubert, Wash. L. Found. Monograph, 1994

Lectures

· Panelist, "Federal Regulation of IRBs: Present and Future," American Bar Association Continuing Legal Education, February 2, 2005

· Presenter, "Daubert - Its Holding and Impact," Judicial Symposium on Construction Defects Litigation, sponsored by AEI-Brookings Joint Center for Regulatory Studies, Judicial Education Program, Washington, D.C., January 27, 2005

· Presenter, "The Hidden Costs of Technology Transfer: the University Perspective," AAAS Colloquium on Science & Technology Policy, Washington, D.C., April 11, 2003

Speeches

· Speaker, Senate Statement before the Special Committee on Aging, July 26, 2001

· Speaker, "FDA Initiatives in Regulating Emerging Technologies - Legal Implications," Food and Drug Law Institute, Washington, D.C., July 23, 1996

· Speaker, "Grappling With Conflicts: How to Keep Off the Front Page of the Post and the Back Page of a Congressional Subpoena. Ethical Issues in Research Relationships," University of Maryland at Baltimore, Baltimore, MD, November 3, 1995

 
ISLN908431906
 

Documents by this lawyer on Martindale.com

Subscribe to this feed

Supreme Court Extends PLIVA to Preempt Certain Design Defect Claims Against Generic Manufacturers
Robert P. Charrow, August 13, 2013
In Mutual Pharm. Co., Inc. v. Bartlett, No. 12-142 (U.S. June 24, 2013), the Supreme Court, in a 5-4 decision building on PLIVA, Inc. v. Mensing, 564 U. S. --- (2011), held that the Food, Drug, and Cosmetic Act preempted a state law design defect action against a generic drug manufacturer that...


View Ratings & Reviews
Profile Visibility
#4,564 in weekly profile views out of 48,190 lawyers in Washington, District of Columbia
#137,516 in weekly profile views out of 1,509,349 total lawyers Overall

Office Information

Robert P. Charrow

2101 L St., N.W., Suite 1000
WashingtonDC 20037




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now